This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) | MicrobiomeTrials
← Back to trials NCT04762498
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) Completed PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-01-26Est. Completion: 2023-05-18
Enrollment target: 54 participantsLocations Orthopedic Physicians Alaska, Anchorage, Alaska, United States Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States East Bay Rheumatology Medical Group, Inc., San Leandro, California, United States ProHealth Research Center, Doral, Florida, United States Napa Research Center, Pompano Beach, Florida, United States GCP Clinical Research, Tampa, Florida, United States The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States Shelby Clinical Research, LLC, Shelby, North Carolina, United States Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States Biopharma Informatic, LLC, Houston, Texas, United States Arthritis Clinic: Western Washington Medical Group, Bothell, Washington, United States Arthritis Northwest PLLC, Spokane, Washington, United States Other microbiome trials you might be interested in Uncontrolled Gout
The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks w…
Birmingham, United States Est. completion Jun 18, 2028
Gout
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of peglotica…
Birmingham, United States Completed Jul 30, 2025